Classic psychedelics are being revisited as novel drug candidates. Researchers are investigating the efficacy of psychedelics for disorders such as depression and addiction. Facets of obesity pathophysiology are neurobiologically similar to these conditions, and we propose that obesity could be the next frontier in psychedelic research.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611–624 (2020).
Huang, J., Pham, M., Panenka, W. J., Honer, W. G. & Barr, A. M. Chronic treatment with psilocybin decreases changes in body weight in a rodent model of obesity. Front. Psychiatry 13, 891512 (2022).
Fadahunsi, N. et al. Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Transl. Psychiatry 12, 330 (2022).
Volkow, N. D., Wang, G.-J., Tomasi, D. & Baler, R. D. Obesity and addiction: neurobiological overlaps. Obes. Rev. 14, 2–18 (2013).
Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79, 953–962 (2022).
Nutt, D. & Carhart-Harris, R. The current status of psychedelics in psychiatry. JAMA Psychiatry 78, 121–122 (2021).
Haahr, M. E. et al. Central 5-HT neurotransmission modulates weight loss following gastric bypass surgery in obese individuals. J. Neurosci. 35, 5884–5889 (2015).
Anderberg, R. H. et al. Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes 66, 1062–1073 (2017).
Simonsson, O., Sexton, J. D. & Hendricks, P. S. Associations between lifetime classic psychedelic use and markers of physical health. J. Psychopharmacol. 35, 447–452 (2021).
Anderson, B. T., Danforth, A. L. & Grob, C. S. Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry 7, 829–830 (2020).
Acknowledgements
Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center based at the University of Copenhagen, Denmark, and partially funded by an unconditional donation from the Novo Nordisk Foundation (www.cbmr.ku.dk) (Grant number NNF18CC0034900).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.C. is co-founder of Ousia Pharma ApS, a biotech company developing therapeutics for obesity. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Fadahunsi, N., Knudsen, G.M. & Clemmensen, C. Do psychedelics have therapeutic potential for obesity?. Nat Rev Endocrinol 19, 1–2 (2023). https://doi.org/10.1038/s41574-022-00769-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-022-00769-1